Elraglusib Combined with Chemotherapy Doubles Survival Rate in Metastatic Pancreatic Cancer Trial

Actuate Therapeutics has announced the publication of clinical trial results in *Nature Medicine* highlighting significant findings regarding the treatment of metastatic pancreatic ductal adenocarcinoma (PDAC). The study reports that combining elraglusib, an investigational drug, with standard chemotherapy doubled the survival rate in patients who had not previously received treatment for this aggressive form of cancer.

The clinical trial focused on patients diagnosed with metastatic PDAC, a condition known for its poor prognosis and limited treatment options. Researchers evaluated the efficacy of elraglusib when administered alongside traditional chemotherapy regimens. According to the published data, patients receiving this combination therapy experienced a twofold increase in survival rates compared to those undergoing standard chemotherapy alone. The findings mark a notable development in ongoing efforts to improve outcomes for individuals battling this challenging disease. Further details on trial methodology and patient demographics were included in the *Nature Medicine* article.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 14, 2026

Author

GOAI